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Abstract
Background: We have recently shown that deregulation PI3-kinase/AKT survival pathway plays an important role in
pathogenesis of diffuse large B cell lymphoma (DLBCL). In an attempt to identify newer therapeutic agents, we investigated
the role of Resveratrol (trans-3,49, 5-trihydroxystilbene), a naturally occurring polyphenolic compound on a panel of diffuse
large B-cell lymphoma (DLBCL) cells in causing inhibition of cell viability and inducing apoptosis.
Methodology/Principal Findings: We investigated the action of Resveratrol on DLBCL cells and found that Resveratrol
inhibited cell viability and induced apoptosis by inhibition of constitutively activated AKT and its downstream targets via
generation of reactive oxygen species (ROS). Simultaneously, Resveratrol treatment of DLBCL cell lines also caused ROS
dependent upregulation of DR5; and interestingly, co-treatment of DLBCL with sub-toxic doses of TRAIL and Resveratrol
synergistically induced apoptosis via utilizing DR5, on the other hand, gene silencing of DR5 abolished this effect.
Conclusion/Significance: Altogether, these data suggest that Resveratrol acts as a suppressor of AKT/PKB pathway leading
to apoptosis via generation of ROS and at the same time primes DLBCL cells via up-regulation of DR5 to TRAIL-mediated
apoptosis. These data raise the possibility that Resveratrol may have a future therapeutic role in DLBCL and possibly other
malignancies with constitutive activation of the AKT/PKB pathway.
Citation: Hussain AR, Uddin S, Bu R, Khan OS, Ahmed SO, et al. (2011) Resveratrol Suppresses Constitutive Activation of AKT via Generation of ROS and Induces
Apoptosis in Diffuse Large B Cell Lymphoma Cell Lines. PLoS ONE 6(9): e24703. doi:10.1371/journal.pone.0024703
Editor: Ben C.B. Ko, Chinese University of Hong Kong, Hong Kong
Received April 30, 2011; Accepted August 16, 2011; Published September 12, 2011
Copyright:  2011 Hussain et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Kkuraya@kfshrc.edu.sa
. These authors contributed equally to this work.
Introduction
Diffuse Large B-cell Lymphoma (DLBCL) is the most common
lymphoid malignancy and constitutes approximately 40% of all
cases [1]. Despite improvement in treatment protocols, treatment
has been shown to cure 50% of all cases and a large number of
DLBCL cases remain refractory to treatment [2,3]. Dysregulated
survival pathways have been shown to contribute to aggressiveness
of DLBCL. We have previously shown that PI39-kinase/AKT
signaling plays a pivotal role in pathogenesis of DLBCL and other
cancer cells by activating AKT and it’s down stream targets,
FOXO-1, GSK-3 and Bad [4,5,6]. AKT prevents apoptosis by
generating anti-apoptotic signals through modulation of the
activity of various survival and pro-apoptotic molecules [7,8].
The Redox system is an essential tool to maintain a balance
between generation and elimination of Reactive oxygen species
(ROS) under physiological conditions in cells [9]. ROS refers to
oxygen-containing breakdown products of molecular oxygen that
are highly reactive and are able to damage lipid membranes,
proteins, and DNA when present in high amounts. ROS release
can induce two types of cell death; necrosis occurs at very high
doses and when cells are exposed to ROS for long duration. On
the other hand, ROS release causes apoptosis at comparably lower
doses and therefore ROS release is being exploited as an anti-
cancer mechanism [10].
Resveratrol is a stilbenoid that is found in the skin of red grapes
and is known to suppress proliferation and induce apoptosis in a
variety of cancer cells [11,12]. Resveratrol has been shown to
inhibit the activation of multiple dysregulated survival pathways
including PI3-kinase/AKT pathway [13,14] to induce apoptosis in
various cancer cells. The exact mode of action of Resveratrol
mediated anticancer effect is not fully understood. Several studies
suggested that Resveratrol induces anti-neoplastic effect by
reacting with cellular peroxidases and thiols thereby transforming
into highly reactive phenoxyl radicals [15]. It has also been shown
that Resveratrol at high concentrations leads to release of ROS in
a variety of cells [16]. In addition, Resveratrol has been known to
release ROS by several indirect pathways as well acting in
association with NAD(P)H- dependent ROS production [17] or at
the mitochondrial level [18]. Recently, it has also been shown that
Resveratrol exerts its anti-proliferative action by arresting cells in
the G1/G2 phase thereby inhibiting cell cycle progression [19].
In this study, we investigated whether Resveratrol inhibited cell
viability and induced apoptosis via inactivation of AKT pathway in
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whether Resveratrol mediates its apoptotic effect via generation of
ROS. We found that Resveratrol indeed induces apoptosis via
inactivation of AKT through generation of ROS. In addition,
Resveratrol treatment of DLBCL cells resulted in upregulation of
DR5 through generation of ROS. This up-regulated DR5
secondary to Resveratrol treatment augmented DLBCL cells to
low doses of TRAIL-induced apoptosis in these malignant cells.
Based on these observations, Resveratrol–TRAIL combination may
offer a new approach in effective treatment of DLBCL.
Materials and Methods
Cell lines
Sudhl4 and Sudhl10 cell lines were purchased from Deutsche
Sammlung von Mikroorganismen und Zellkulturen (DSMZ),
Braunschweig, Germany. HBL-1, OCI-LY3 and RIVA were a
kind gift from Dr Laura Pasqualucci Institute for Cancer Genetics
and the Herbert Irving Comprehensive Cancer Center, Columbia
University, New York, USA. Sudhl4 and Sudhl10 cell lines were
cultured in RPMI 1640 medium while HBL-1, OCI-LY3 and
RIVA cell lines were grown in IMDM medium. All the
experiments were performed in media containing 5% serum.
Reagents and antibodies
Resveratrol was purchased from Calbiochem (Gibbstown, NJ).
Bax (6A7) antibody, PEG-catalase and PEG-superoxide dismutase
were purchased from Sigma (St. Louis MO, MA). Antibodies
against p-AKT, caspase-9, p-FOXO-1, p-GSK3, p-Bad, cleaved
caspase-3 and Bid were purchased from Cell Signaling Technol-
ogies (Beverly, MA, USA). Cytochrome c, beta-actin, caspase-3,
SHP-TP1, p-Tyr and PARP antibodies were purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). XIAP, cIAP-1,
cIAP-2, Survivin and caspase-8 antibodies were purchased from
R&D (USA). Annexin V was purchased from Molecular Probes
(Eugene OR, USA). Apoptotic DNA-ladder kit was obtained from
Roche (Penzberg, Germany). H2DCFDA and JC1 dye were
purchased from Alexis Corp (Farmingdale, NY, USA).
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide Assays
DLBCL cells were incubated at the concentration of 10
4 cells in
triplicates in a 96 well format. Cells were then treated with various
doses of Resveratrol for 48 hours in a final volume of 0.2ml for
48 hours. Cell viability was measured by MTT cell viability assay,
as previously described [5,20]. 6 wells for each dosage including
vehicle control were analyzed for each experiment. * denotes
statistical significance.
Live Dead Assay
To measure apoptosis, Live-Dead assay (Invitrogen, Eugene,
OR) was used as described by the manufacturer. Briefly, 1610
6
DLBCL cells were treated with various doses of Resveratrol or
TRAIL for 24 hours. Following incubation, cells were re-
suspended in 1ml PBS containing 50 mM calcein AM and 8 mM
ethidium homodimer and cells were incubated in the dark for
20 minutes. 50 ml of suspension was transferred on slides and
visualized under an Olympus fluorescent microscope using a
longpass filter.
Cell cycle analysis, annexin V staining, and DNA laddering
DLBCL cell lines were treated with various concentrations of
Resveratrol for 24 hours. For cell cycle analysis, cells were washed
with PBS and re-suspended in 500ml hypotonic staining buffer and
analyzed by flow cytometry as described previously [21]. For
detection of apoptosis, cells were harvested and percentage
apoptosis was measured by flow cytometry after staining with
flourescein-conjugated annexin-V and propidium iodide (PI)
(Molecular probes, Eugene, OR) and DNA laddering using a
1.5% agarose gel as described previously [22].
Soft agar colony assays
Soft agar colony experiments were performed according to the
manufacturer’s protocol (Cheminon International, Temecula,
CA). Briefly, following treatment with indicated doses of
Resveratrol, 2500 cells were plated in 0.5ml culture medium
containing 0.4% (v/v) top agar and layered over a basal layer of
0.8% (v/v) agar and 20% FBS with culture medium and allowed
to grow for 4 weeks. Following 4 weeks incubation, cells were
stained at a final concentration of 1mg/ml cell stain solution that
was supplied with the kit.
Measurement of ROS
We used H2DCFDA, a cell permeable fluorescent probe for
detection for ROS release as described earlier [21]. Briefly, 1x10
6
exponentially growing cells were loaded with 10 mM H2DCFDA
for 45 minutes at 37uC and then treated with Resveratrol for
various time periods in presence of 10mM NAC. Following
incubation, the cells were washed with PBS and green fluorescence
intensity in the cells was examined by FACS analysis.
Cell lysis and Immunoblotting
For immunoblotting analysis, we extracted protein from
Resveratrol treated cells as described previously [23]. Briefly,
following treatment of DLBCL, cell were collected and were re-
suspended in phosphorylation lysis buffer that contained 0.5–1.0%
TritonX-100, 150mM NaCl, 1mM EDTA, 200mM sodium
orthovanadate, 10mM sodium pyrophosphate, 100mM sodium
fluoride, 1.5mM magnesium chloride, 1mmol/L phenylmethyl-
sulfonyl-flouride, and 10mg/ml aprotonin. Bradford assay was
used to assess protein concentrations and equal amount of proteins
were separated by SDS-PAGE and transferred to polyvinylidene
difluoride membrane (Immobilion, Millipore, etc). Immunoblot-
ting was performed with different antibodies and visualized by an
enhanced chemiluminescence (ECL, Amersham, Illinois, USA)
method.
Detection of Bax conformational changes
Detection of Bax conformation was performed as previously
described [24]. In brief, cells were treated with Resveratrol for
different time periods after which cells were harvested and washed
with PBS and lysed with Chaps lysis buffer (10mM HEPES (ph
7.4), 150mM NaCl, 1% Chaps) containing protease inhibitors.
Concentration of proteins was assessed by Bradford assay and
500 mg of total protein was incubated with 6 mg of anti-Bax 6A7
monoclonal antibody for 2 hours at 4uC. Following incubation,
25 ml of protein G-beads were added into the reaction and
incubated at 4uC overnight on a shaker with gentle agitation.
Following 4 washes in Chaps lysis buffer, samples were separated
by SDS-PAGE, transferred and immunoblotted using N20 Bax
polyclonal antibody.
Assay for cytochrome c release
Release of cytochrome c from mitochondria was assayed as
described earlier [24]. Briefly, After treatment of DLBCL cells
with Resveratrol for 24 hours, cells were harvested, washed with
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immunoblotting using an anti-cytochrome c antibody.
Measurement of mitochondrial potential using the JC-1
(5, 59,6 ,6 9-teterachloro-1, 19, 3,39-
tetraethylbenzimidazolylcarbocyanine iodide) assay
1x106 cells were treated with Resveratrol for 24 hours after
which the cells were washed with PBS and re-suspended in
mitochondrial incubation buffer (Alexis Corporation, Farming-
dale, NY, USA). JC1 (Alexis corp) was then added to the cells at a
final concentration of 10mM and incubated at 37uC in dark for 30
minutes and mitochondrial membrane potential (% of green and
red aggregates) was determined by flow cytometry as described
previously [25].
In vitro kinase assay
AKT kinaseassay (Abcam, ab65786, Cambridge, MA, USA) was
performed according to the manufacturer’s protocol. Briefly,
DLBCL cells were treated with various doses of Resveratrol for
24 hours. Following treatment, cells were pelleted (10–15610
6) and
washed once with ice cold PBS and lysed in ice cold kinase
extraction buffer. For each assay, 2 mg of AKT specific antibody
and protein A beads were added to 200 mg proteins and incubated
overnight at 4uC with gentle agitation. Next day, cells were pelleted
and washedwithkinaseextractionbufferand once with kinaseassay
buffer. 50 ml Kinase Assay Buffer and 2 ml GSK-3 alpha Protein/
ATP Mixture was added to the protein A beads and incubated at
30uC for 4 hours. After incubation, protein A beads were spun,
boiled and separated by SDS-PAGE, transferred to polyvinylidene
difluoride membrane and probed with p-GSK3 antibody.
RT-PCR assays
Total RNA was extracted following treatment with 25 and
50 mM apigenin for 24 hours using TRIZOL and reverse-
transcribed with random hexamers. RT-PCR amplifications were
performed using the following primers:
AKT1-For: GCTGGACGATAGCTTGGA
AKT1-Rev: GATGACAGATAGCTGGTG,
AKT2-For: GGCCCCTGATGAGACTCTA,
AKT2-Rev: TCCTCAGTCGTGGAGGAGT, and
AKT3-For: GCAAGTGGACAGGAATAAGTCTC,
AKT3-Rev: ACAATGGTGGGCTCATGACTTCC
for 35 cycles (55uC annealing temperature) to yield 382bp, 275bp
and 328bp products respectively. Amplification of GAPDH was
used as an internal control.
Gene Silencing using SiRNA
DR5 siRNA (cat no. S100056707 and cat no. S100056700 pooled)
and Scrambled control siRNA (cat no. 102781) were purchased from
Qiagen. The method used for transfection was the same as previously
described [5]. In brief, cells were washed with serum free media and
re-suspended in a complex containing LipofectAMINE 2000 reagent
(Invitrogen, Carlsbad, CA) and the desired siRNA for 6hours. After
incubation, the lipid and siRNA complex was removed and fresh
growth medium was added. Cells were treated 48 hours after
transfection for 24 hours and specific protein levels were determined
by Western Blot analysis with specific antibodies against the targeted
proteins and actin as a loading control.
Statistical Analysis
Data are presented, as mean 6 SD. Comparisons between
groups were made with the paired Student’s t-test. Values of
p,0.05 were considered statistically significant.
Results
Resveratrol treatment causes inhibition of viability and
induces apoptosis in DLBCL cell lines
Resveratrol has been previously shown to inhibit cell viability
and induce apoptosis in various cancers [26,27]; therefore, we
initially sought to determine whether Resveratrol induced
inhibition of cell viability and induced apoptosis in DLBCL cells.
DLBCL cells were treated with 5, 10, 25, 50 and 100 mM
Resveratrol for 48 hours and analyzed for cell viability by MTT
assays. As shown in Figure 1A, there was dose dependent
inhibition in cell viability in all cell lines tested and this inhibition
reached statistical significance for most of the doses. We then
examined cells under a microscope after staining them with calcein
and ethidium homodimer to check for plasma membrane integrity
following treatment with 25 and 50 mM Resveratrol for 24 hours.
As shown in Figure 1B, untreated cells were stained green
depicting alive cells with plasma membrane integrity intact while
cells treated with Resveratrol showed an increase of red cells
suggesting disruption of plasma membrane integrity, i.e., dead
cells. Next we treated DLBCL cells with 25 and 50 mM
Resveratrol for 24 hours and determined the cell cycle fractions
by flow cytometry. Following treatment with Resveratrol, there
was an increase in the subG1/Apo fraction of cells from 6.02% to
44.92% and 83.82% after treatment with 25 mM and 50 mM
Resveratrol in SUDHL4 cell line. Similar results were obtained in
other DLBCL cell lines (Figure 1C). We analyzed Resveratrol
treated DLBCL cell lines for apoptosis after FITC-conjugated
annexin V and propidium iodide (PI) staining by flow cytometry.
As shown in Figure 1D, we found that SUDH4 cell line had 42%
and 71% apoptosis, SUDHL10 (47% and 80%), HBL-1 (57% and
66%), OCI-LY3 (62% and 69%) and RIVA (59% and 64%) after
25 and 50 mM Resveratrol treatment respectively. These data
were finally confirmed by DNA laddering test that showed
fragmentation of chromosomal DNA into 180bp bands in
SUDHL4 and HBL-1 following treatment with 25 and 50 mM
Resveratrol (Figure S1A). We also performed soft agar colony
assays following treatment with 25 and 50 mM Resveratrol for 4
weeks. As shown in Figure S1B and C, Resveratrol treatment
inhibited colony formation in HBL-1 cell line. These set of data
clearly demonstrated that Resveratrol treatment inhibited cell
viability and induced apoptosis in DLBCL cell lines.
Resveratrol treatment causes in-activation of AKT and its
down-stream targets in DLBCL cells
Resveratrol has been shown to disrupt various survival pathways
including PI3-kinase/AKT pathway in various cancers [28,29]. For
this reason, we sought to determine whether Resveratrol was
inducing pro-apoptotic action via in-activation of PI3-kinase/AKT
activity in DLBCL cells. SUDHL4 and HBL-1 cell lines were
treated with 25 and 50 mM Resveratrol for 24 hours and proteins
were extracted and immuno-blotted with antibodies against
activated-AKT, total AKT and its downstream targets. As shown
in Figure 2A, constitutive activation of AKT was in-activated
following treatment with Resveratrol in both the cell lines; however,
there was no effect on expression of total AKT. In addition,
Resveratrol treatment of PEL cells did not affect the transcript levels
of AKT1, AKT2 and AKT3 as well when detected by RT-PCR
(Figure S2A). Forkhead Box-O (FOXO-1), a downstream target of
AKT is emerging as a key regulator of cell survival in various
cancers [30]. Resveratrol treatment of DLBCL cells also in-
activated FOXO-1 without affect the expression of total Foxo-1
protein in a dose dependent manner in both the cell lines. GSK-3 is
another down-stream target of AKT and plays an important role in
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GSK-3 in DLBCL cell lines. In addition, we also determined
whether Resveratrol in-activated phosphorylation of Bad, another
target of AKT that plays an important role in activating the
mitochondrial apoptotic pathway. As shown in Figure 2A, Resver-
atrol treatmentalsocausedin-activationofBadinboth the cell lines.
Finally, we assessed whether Resveratrol inhibited AKT kinase
activity in DLBCL cells. SUDHL4 cells were treated with 25 and
50 mM Resveratrol for 24 hours and cell lysates were immunopre-
cipitated with an anti-AKT antibody or rabbit IgG, and in vitro
kinase assays were performed as described in material and method
section. Resveratrol treatment resulted in inactivation of AKT
activity and dephosphorylation of GSK3 in SUDHL4 cells
(Figure 2B). This data suggests that Resveratrol treatment causes
inhibition of kinase activity of AKT in DLBCL cells.
Resveratrol causes release of ROS in DLBCL cell lines
The exact mode of action of Resveratrol is not actually known,
however, it has been suggested that Resveratrol acts via release of
ROS [13,14]. Therefore, it became pertinent to us to detect
whether Resveratrol treatment of DLBCL cells was causing ROS
release. SUDHL4 and HBL-1 cells were therefore loaded with
H2DCFDA and then treated with 50 mM Resveratrol for various
time periods and cells were analyzed by flow cytometry. As shown
in Figure 2C, Resveratrol treatment caused release of ROS, as
early as 2 hours that continued up to 8 hours of treatment in
SUDHL4 and HBL-1 cell lines. This data was confirmed by pre-
treating the cells with NAC, a scavenger of ROS for 2 hours
followed by treatment with Resveratrol. As shown in Figure 2D,
NAC pre-treatment significantly abrogated ROS release in both
cell lines. To further confirm whether ROS release plays a major
Figure 1. Resveratrol suppresses growth and induces apoptosis in DLBCL cells. (A) DLBCL cell lines were incubated with 0–100 mM
Resveratrol for 24 hours. Cell viability was measured by MTT assays as described in Materials and Methods. The graph displays the mean +/2 SD
(standard deviation) of three independent experiments, * p,0.05, statistically significant (Students t-test). (B) SUDHL4, HBL-1 and OCILY3 cells were
treated with 25 and 50 mM Resveratrol for 24 hours and apoptosis was measured by Live/Dead Assay. (C) DLBCL cells were treated with 25 and 50 mM
Resveratrol for 24 hours. Thereafter, the cells were washed, fixed and stained with propidium iodide, and analyzed for DNA content by flow
cytometry as described in ‘‘Materials and methods’’. (D) DLBCL cells were treated with 25 and 50 mM Resveratrol (as indicated) for 24 hours and cells
were subsequently stained with flourescein-conjugated annexin-V and propidium iodide (PI) and analyzed by flow cytometry.
doi:10.1371/journal.pone.0024703.g001
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treated with various doses of Resveratrol. Equal amount of protein from each sample was immunoblotted with Phospho-Akt-Ser473, total AKT
Phospho-FOXO1, total FOXO1, p-GSK3, Phospho-Bad and Beta-actin. (B) SUDHL4 cells were treated with 25 and 50 mM Resveratrol for 24 hours. Cells
were lysed and immunoprecipitated with either AKT antibody or IgG along with protein A beads overnight. After incubation, beads were washed and
incubated with kinase buffer and 2 ml GSK-3 Protein/ATP mixture at 30uC for 4 hours. Beads were boiled and equal amount of protein was
immunoblotted with antibody against p-GSK3. (C) SUDHL4 and HBL-1 cells were loaded with 10 mM H2DCFDA for 45 minutes and then were
incubated with 25 mM Resveratrol for indicated time periods. Cells were re-suspended in PBS and analyzed for intracellular accumulation of H2DCFDA
by flow cytometry (D) SUDHL4 and HBL-1 cell lines were loaded with 10 mM H2DCFDA for 45 minutes and then were pre-treated with 10mM NAC for
2 hours followed by treatment with 50 mM Resveratrol for various time periods. Cells were re-suspended in PBS and analyzed using flow cytometry.
Bar graph displays the mean +/2 SD (standard deviation) of three independent experiments, * p,0.05, statistically significant (Students t-test). (E)
SUDHL4 and HBL-1 cells were pretreated with 10mM NAC for 2 hours followed by treatment with 50 mM Resveratrol for 24 hours. After cell lysis,
equal amounts of proteins were immunoblotted with antibodies against p-AKT and beta actin as indicated.
doi:10.1371/journal.pone.0024703.g002
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DLBCL cells with either PEG-catalase or PEG-superoxide
dismutase (SOD) for 2 hours followed by treatment with 50 mM
Resveratrol for 24 hours. As shown in Figure S1D, PEG-catalase
and PEG-SOD pre-treatment significantly inhibited Resveratrol
induced apoptosis in DLBCL cells.
Resveratrol in-activates AKT via release of ROS
To better understand the role of ROS release in in-activation of
AKT, we pre–treated DLBCL cells with 10mM NAC for 2 hours
followed by treatment with Resveratrol for 24 hours. Proteins
were prepared and immuno-blotted with antibodies against p-
AKT and Beta-actin. As shown in Figure 2E, Resveratrol
treatment in-activated AKT but pre-treatment with NAC
prevented Resveratrol-induced in-activation of AKT. This data
clearly demonstrates that Resveratrol treatment causes release of
ROS that, in turn, causes in-activation of AKT. The exact
mechanism by which ROS release leads to in-activation of AKT is
not known. However, there are reports that suggest that AKT can
be de-phosphorylated by various phosphatases such as PTEN and
SHPTP1 [32,33,34,35]. We found that PTEN expression was not
altered by Resveratrol treatment (Data not shown) of DLBCL cells
suggesting that PTEN is not involved in Resveratrol-mediated in-
activation of AKT. SHP-TP1, a tyrosine phosphatase has been
shown to regulate the activity of AKT [35]. Therefore, we next
determined whether Resveratrol treatment could modulate the
activity of SHP-TP1 in DLBCL cells. SUDHL4 cells were treated
with either 25 or 50 mM Resveratrol alone or in the presence of
NAC. Following treatment, cells were lysed and immunoprecip-
itated with either SHP-TP1 antibody or rabbit IgG as indicated in
Figure S2B. Proteins were separated on SDS-Page and immuno-
blotted with antibody against p-Tyrosine. Our data indicated that
Resveratrol treatment led to activation (phosphorylation) of SHP-
TP1 in a dose dependent manner and this activation was blocked
by pre-treatment L with NAC. These data suggests that
Resveratrol-mediates the induction of SHP-TP1 activity in a
ROS dependent manner in DLBCL cells.
Resveratrol treatment causes activation of mitochondrial
apoptotic pathway and release of cytochrome c into
cytosole in DLBCL cells
In-activation of Bad has been shown to activate the mitochon-
drial apoptotic pathway by allowing Bad protein to translocate to
mitochondria leading to up-regulation of pro-apoptotic Bax [36].
To examine whether this theory hold true for Resveratrol-induced
activation of mitochondrial apoptotic pathway, we treated
SUDHL4 and HBL-1 cell lines with 50 mM Resveratrol for
various time periods and then examined the conformational
changes in Bax protein by immuno-precipitation. We found
evidence that Bax protein underwent conformational changes, as
early as 2 hours in HBL-1 cell line and 4 hours in SUDHL4 cell
line (Figure 3A). To confirm whether Bax conformational changes
was due to ROS release and not due to activation of caspases, we
pre-treated HBL-1 cells with either 10mM NAC or 80 mM zVAD-
fmk for 2 hours followed by treatment with 50 mM Resveratrol for
8 hours and Bax conformation changes were detected by immuno-
blotting. As shown in Figure 3B, Bax conformational changes were
blocked only in NAC pre-treated cells following treatment with
Resveratrol. This data suggested that ROS release is required for
activation of Bax protein in DLBCL cell lines treated with
resveratrol. We next treated all the DLBCL cell lines with 25 and
50 mM Resveratrol for 24 hours and then stained the cells with
JC1 and analyzed the cells by flow cytometry and found that
DLBCL cells treated with Resveratrol had an increase in green
stained apoptotic cells as compared to normal cells that stained red
(Figure 3C) confirming change in mitochondrial membrane
potential. Once there are changes in the mitochondrial membrane
potential, it leads to release of cytochrome c into cytosole. To
assess this, we prepared mitochondrial free cytosolic extracts of
SUDHL4 and HBL-1 cell lines treated with Resveratrol and
immuno-blotted them with antibody against cytochrome c. As
shown in Figure 3D, the cytosolic fraction showed an increase in
cytochrome c expression following treatment with Resveratrol in
both, SUDHL4 and HBL-1 cell lines. This data clearly suggests
that Resveratrol treatment caused release of cytochrome c in
DLBCL cells. Inhibitor of apoptosis proteins (IAPs) plays a very
important anti-apoptotic role by inhibiting the activation of
caspase-9 and/or caspase-3 thereby preventing the apoptotic
signal to proceed. Therefore, we wanted to examine whether
Resveratrol treatment of DLBCL cells down-regulated the
expression of these proteins as well. Resveratrol treatment of
DLBCL caused down-regulation of IAP family members, XIAP,
cIAP1 and Survivin in a dose dependent manner (Figure S3).
Caspases activation is essential for Resveratrol-induced
apoptosis in DLBCL
For efficient apoptosis to occur, the caspases family of proteins
needs to be activated and cleaved, whether the apoptotic signal is
initiated by the extrinsic or intrinsic apoptotic pathway. To
analyze the caspases, we treated SUDHL4 and HBL-1 cells with
25 and 50 mM Resveratrol for 24 hours and assessed for caspase
activation and cleavage by immuno-blotting. As shown in
Figure 4A, caspases-9 and -3 were activated and cleaved followed
by cleavage of PARP in both the cell lines. To confirm whether
caspase activation is necessary for induction of apoptosis, we pre-
treated DLBCL cells with a universal inhibitor of caspases, zVAD-
fmk for 2 hours followed by 24 hour treatment of Resveratrol.
zVAD-fmk pre-treatment inhibited Resveratrol-induced activation
of caspases-9, -3 and cleavage of PARP (Figure 4B). In addition,
we also wanted to know whether ROS release played any role in
activation and cleavage of caspases. Therefore, we pre-treated
DLBCL cells with 10mM NAC for 2 hours followed by treatment
with Resveratrol for 24 hours. As seen in Figure 4C, NAC pre-
treatment prevented Resveratrol-induced activation of caspases-9
and -3 and cleavage of PARP. In addition, DLBCL cells pre-
treated with either zVAD-fmk or NAC also prevented Resveratrol-
induced apoptosis (Figure 4D). These set of data suggest that
caspases activation is essential for Resveratrol-induced apoptosis
however Resveratrol induces its apoptotic action via release of
ROS.
Resveratrol-induced release of ROS causes up-regulation
of DR5 in DLBCL cells
Tumor necrosis factor related apoptosis inducing ligand
(TRAIL) has the ability to selectively kill cancer cell, however,
resistance to TRAIL quickly develops in cancer cells [37]. Death
Receptor 5 (DR5) has been shown to be up-regulated by ROS
release [21], therefore, we sought to determine whether Resver-
atrol-induced release of ROS caused up-regulation of DR5 in
DLBCL cells. SUDHL4 and HBL-1 cells were treated with 50 mM
Resveratrol for various time periods and proteins were separated
on SDS-Page and immuno-blotted with antibody against DR5.
Resveratrol treatment caused up-regulation of DR5 within 4hours
and continued to be up-regulated up to 24 hours (Figure 5A). We
next pre-treated DLBCL cells with either 80 mM zVAD-fmk or
10mM NAC for two hours followed by treatment with 50 mM
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zVAD-fmk pre-treatment did not inhibit Resveratrol-induced up-
regulation of DR5 while NAC pre-treatment blocked DR5 up-
regulation Figure 5B (lower panel) clearly suggesting that DR5 up-
regulation does not depend upon caspase-activation but on ROS
release.
DR5 does not play a role in Resveratrol-induced
apoptosis in DLBCL cells
TRAIL has the ability to induce apoptosis through interacting
with its death receptors [38]. It has also been shown that up-
regulation of DR5 alone is not sufficient to induce apoptosis and
requires its ligand, TRAIL for efficient apoptosis to occur [39]. We
therefore sought to determine whether DR5 up-regulation alone
plays an active role in Resveratrol-induced apoptosis in DLBCL
cells. Therefore, we transfected SUDHL4 and HBL-1 cells with
siRNA against DR5 for 48 hours and then treated the cells with 25
and 50 mM Resveratrol for 24 hours. As shown in Figure 5C, DR5
knockdown of DLBCL cells did not prevent Resveratrol-induced
apoptosis as measured by annexin V/PI dual staining analyzed by
flow cytometry. In addition, caspase -3 was also activated and
PARP was cleaved in DR5 knockdown cells treated with
Resveratrol (Figure 5D). This data suggests that even though,
Resveratrol has the ability to up-regulate DR5, this up-regulation
does not play a role in Resveratrol-induced apoptosis in DLBCL
cells.
Resveratrol and TRAIL induces synergistically potent
apoptosis in DLBCL cells
In order to utilize up-regulation of DR5 effectively to induce a
more potent apoptosis, we treated DLBCL cell lines with a
combination of sub-toxic doses of Resveratrol (10 mM) and
TRAIL (1 and 5ng) for 24 hours and assessed the apoptotic
response. As shown in Figure 6A, neither Resveratrol nor TRAIL
at sub-toxic doses could induce apoptosis alone, however, when
both the drugs were given in combination, there was efficient
apoptosis in SUDHL4 and HBL-1 cell lines. In addition,
combination of Resveratrol and TRAIL was also able to activate
caspase-8, caspase-3 and cleave PARP (Figure 6B). To confirm
these findings, we knocked down the expression of DR5 using
specific siRNA against DR5 followed by combination treatment of
sub-toxic doses of Resveratrol and TRAIL for 24 hours in DLBCL
cells. As expected, we found that DLBCL cells that were
transfected with scrambled non-specific siRNA showed a syner-
gistic apoptotic response to the combination treatment; however,
in those cells that were transfected with siRNA against DR5, there
was a diminished apoptotic response following combination
treatment of Resveratrol and TRAIL at sub-toxic doses
Figure 3. Resveratrol-induced mitochondrial signaling pathway in DLBCL cells. (A) After treating with 50 mM Resveratrol for indicated time
periods, HBL-1 and SUDHL4 cells were lysed and immuno-precipitated with anti-Bax 6A7 antibody for detection of conformationally changed Bax
protein. In addition, the total cell lysates were immuno-blotted with specific anti-Bax polyclonal antibody. (B) HBL-1 and SUDHL4 cells were pre-
treated with either, 10mM NAC and 80 mM z-VAD/fmk for 2 hours and subsequently treated with 50 mM Resveratrol for 8 hours. Cells were lysed and
immunoprecipitated with anti-Bax 6A7 antibody and proteins were immunoblotted with Bax rabbit polyclonal antibody. (C) DLBCL cells were treated
with and without 25 and 50 mM Resveratrol for 24 hours. Live cells with intact mitochondrial membrane potential and dead cells with lost
mitochondrial membrane potential was measured by JC-1 staining and analyzed by flow cytometry as described in Materials and Methods. (D)
SUDHL4 and HBL-1 cells were treated with 25 and 50 mM Resveratrol for 24 hours. Mitochondrial free cytosolic fractions were isolated and
immunoblotted with antibody against cytochrome c and Beta-actin.
doi:10.1371/journal.pone.0024703.g003
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that there was up-regulation of DR5 in SUDHL4 and HBL-1 cells
transfected with scrambled siRNA following Resveratrol treat-
ment, however, the expression of DR5 in DLBCL cells transfected
with siRNA against DR5 was diminished or absent even after
treatment with Resveratrol (Figure 6E). These data suggest that
Resveratrol augmentation of TRAIL induced apoptosis occurs via
up-regulation of DR5.
Discussion
Induction of apoptosis in malignant cells is a very important
mechanism of action of anticancer drugs [40]. Resveratrol (3,5,49-
trihydroxy-trans-stilbene) is a stilbenoid, produced naturally by
several plants has been shown to have anticancer activity in vitro
and animal studies [11,26,27]. We now provide evidence that
Resveratrol induces cell death and apoptosis in a panel of diffuse
large B cell lymphoma (DLBCL) cell lines. We have recently
shown that activated AKT was present in 52% of DLBCL tumor
cells [6]. Furthermore, high p-AKT expression was associated with
short survival, thereby suggesting that the PI3K/AKT pathway
may be a potential target for therapeutic intervention in DLBCL.
In this study, we found that Resveratrol induces its pro-apoptotic
effects via inactivation of AKT and its downstream targets;
FOXO1, GSK3 and Bad.
The exact mechanism of action of Resveratrol is not fully
understood, however, it has been proposed that Resveratrol causes
its pro-apoptotic effects via generation of ROS in various cancers
[13,14]. We confirm these findings by clearly demonstrating by
H2DCFDA based experiments that Resveratrol treatment causes
release of ROS in DLBCL cells. Furthermore, we also show that
Resveratrol-induced inactivation of AKT is also ROS release
dependent as pre-treatment of DLBCL cells with N-acetyl cysteine
(NAC), a scavenger of ROS inhibited Resveratrol-induced
Figure 4. Activation of caspases -9, -3 and cleavage of PARP induced by Resveratrol treatment in DLBCL cells. (A) SUDHL4 and HBL-1
cells were treated with and without 25 and 50 mM Resveratrol for 24 hours. Cells were lysed and equal amounts of proteins were immunoblotted
with antibodies against caspase-9, caspase-3, cleaved caspase-3, PARP and Beta-actin. SUDHL4 and HBL-1 cells were pretreated with either 80 mMz -
VAD (B) or 10mM NAC (C) for 2 hours and subsequently treated with 50 mM Resveratrol for 24 hours. Cells were lysed and equal amounts of proteins
were immunoblotted with antibodies against caspase-9, caspase-3 cleaved caspase-3 and beta-actin. (D) SUDHL4 and HBL-1 cells were pretreated
with either 80 mM of z-VAD-fmk or 10mM NAC for 2 hours and subsequently treated with 50 mM Resveratrol for 24 hours. Following treatment, cells
were stained with fluorescein conjugated annexinV/PI and apoptosis was measured by flow cytometry.
doi:10.1371/journal.pone.0024703.g004
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catalase and PEG-SOD were also used to confirm the role of ROS
release in inducing apoptosis in DLBCL. The exact mechanism by
which Resveratrol-induced ROS release leading to in-activation of
p-AKT is not known. Our data suggests that Resveratrol-induced
ROS release activate the tyrosine phosphatase, SHP-TP1 resulting
in de-phosphorylation of AKT. Therefore, these finding implicate
that Resveratrol inhibits AKT activity via modulation of SHP-TP1
through the release of ROS in DLBCL cells.
The mitochondrial apoptotic pathway plays an important role
on inducing apoptosis via activation of pro-apoptotic molecules
such as Bax leading to release of cytochrome c into cytosole and
activation of caspases [41]. Resveratrol mediated its apoptotic
effects in DLBCL cells via in-activation of Bad leading to
conformational changes in Bax protein and its translocation into
the mitochondrial membrane. Once Bax is translocated to the
mitochondrial membrane, it renders the membrane leaky thereby
causing changes in the mitochondrial membrane potential. Loss of
mitochondrial membrane potential is one of the main mechanisms
responsible for cytochrome c release in response to different
cytotoxic stimuli. In cytosol, cytochrome c plays a key role by
activating pro-caspase 9 in the presence of ATP. This in turn
causes cleavage of caspase-9 that propagates the death signal by
activating caspase-3 and causing cleavage of PARP. Activation
and cleavage of PARP is the hallmark of apoptosis that in turn
causes DNA fragmentation and cell death.
There are studies that have shown that ROS release sensitizes
cancer cells to TRAIL induced apoptosis via up-regulation of DR5
in various cancers [42,43,44,45,46]. In concordance with these
studies, our data also showed that Resveratrol treatment of
Figure 5. Reservatrol-mediated upregulation of DR5. (A) SUDHL4 cells were treated with 50 mM Resveratrol for indicated time periods. After
cell lysis, equal amounts of proteins were immuno-blotted with antibodies against DR5 and beta actin. (B) SUDHL4 and HBL-1 cells were pre-treated
with either 80 mM of z-VAD (upper panel) or 10mM NAC (lower panel) for 2 hours and subsequently treated with 50 mM Resveratrol for 24 hours.
Cells were lysed and equal amounts of proteins were immunoblotted with antibodies against DR5 and beta-actin. (C) SUDHL4 cells were either
transfected with 50 and 100nM siRNA, specific against DR5 or scrambled siRNA for 48 hours. Cells were then treated with 25 and 50 mM Resveratrol
for 24 hours, following which cells were stained with fluorescent-conjugated Annexin V/PI and analyzed by flow cytometry. (D) SUDHL4 cells were
either transfected with 100nM siRNA, specific against DR5 or scrambled siRNA for 48 hours and treated with 25 and 50 mM Resveratrol for 24 hours.
Cells were lysed and equal amounts of proteins were immuno-blotted with antibodies against DR5, caspase-3, cleaved caspase-3, PARP and beta-
actin.
doi:10.1371/journal.pone.0024703.g005
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However, up-regulation of DR5 did not play a role in inducing
apoptosis in these cell lines. We confirmed these finding by
knocking down expression of DR5 in DLBCL cell lines,
Resveratrol was still able to induce efficient apoptosis as was
evident by flow cytometry results and immuno-blotting that
showed activation of caspases and cleavage of PARP in
Resveratrol-treated DLBCL cells. Horndasch et al have recently
shown that Resveratrol sensitized prostate cancer cells to TRAIL-
induced apoptosis [47]. In concordance to this study, we were also
able to synergize DLBCL cells with Resveratrol to TRAIL-
induced apoptosis. Indeed, up-regulation of DR5 by Resveratrol
treatment does give an added attractive target to induce more
potent apoptosis without causing toxicity by using combination
treatment with sub-toxic doses of Resveratrol and TRAIL. These
experiments allow us to utilize the intrinsic as well as the extrinsic
Figure 6. Resveratrol treatment potentiates TRAIL mediated apoptosis in DLBCL cells. (A) SUDHL4 and HBL-1 cells were treated with
either 10 mM Resveratrol in the presence and absence of 1 and 5ng TRAIL for 24 hours. Following treatment, cells were stained with fluorescent-
conjugated Annexin V/PI and analyzed by flow cytometry. (B) SUDHL4 cells were treated with either 10 mM Resveratrol in the presence and absence
of 1 and 5ng TRAIL for 24 hours. Following treatment, cells were lysed and equal amounts of proteins were immuno-blotted with antibodies against
caspase-8, caspase-3, PARP, and beta- actin. (C) SUDHL4 and HBL-1 cells were transfected with either scrambled siRNA (100nM) or DR5 specific siRNA
(100nM) for 48 hours and then cells were treated with 10 mM Resveratrol in the presence of either 1 or 5ng TRAIL for 24 hours following which cells
were stained with fluorescent-conjugated Annexin V/PI and analyzed by flow cytometry, * denotes statistical significance (p,0.05) or (D) cells were
stained with 50 mM calcein AM and 8 mM ethidium homodimer and visualized under an Olympus fluorescent microscope using a long-pass filter. (E)
SUDHL4 and HBL-1 cells were transfected with either scrambled siRNA (100nM) or DR5 specific siRNA (100nM) for 48 hours and then cells were
treated with 0 mM Resveratrol in the presence of either 1 or 5ng TRAIL for 24 hours following which cells were lysed and immunoblotted with
antibodies against DR5 and Betaactin.
doi:10.1371/journal.pone.0024703.g006
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of DR5 by Resveratrol hence sensitizes DLBCL cells to TRAIL-
induced apoptosis and therefore has potential clinical application
in the management of B-cell malignancies. To our knowledge, this
is the first report on the ability Resveratrol to augment TRAIL’s
apoptotic effects via upregulation of DR5 in DLBCL.
In summary our findings show (Schematic proposed in Figure 7)
that Resveratrol-induced apoptosis occurs via release of ROS.
ROS release led to in-activation of AKT and its down-stream
targets; FOXO1, GSK3 and Bad. Once Bad is in-activated, it
allowed conformational changes in Bax protein leading to change
in mitochondrial membrane potential, release of cytochrome c
into cytosole and apoptosis via the intrinsic apoptotic pathway. In
addition, ROS release also caused up-regulation of DR5 and co-
treatment of DLBCL cells with Resveratrol and TRAIL
significantly enhanced apoptosis in DLBCL. These data demon-
strates a viable strategy of therapeutic intervention for the
management of DLBCL.
Supporting Information
Figure S1 Anticancer effects of Resveratrol on DLBCL
cells. (A) HBL-1 and SUDHL4 cells were treated with 25 and
50 mM Resveratrol for 24 hours and DNA was extracted and
separated by electrophoresis on 1.5% agarose gel. (B) Clonogenic
assays were performed as described in Materials and Methods.
BC1 cells were treated with 25 and 50 mM Resveratrol for
24 hours. Subsequently, cells were plated in Soft agar plates for 4
weeks. Cells were stained and manually counted. (C) The bar
graph displays the mean 6 standard deviation of three
independent experiments. * denotes statistically significant stu-
dents ttest (p,0.05). (D) HBL-1 and SUDHL4 cells were treated
with 50 mM Resveratrol for 24 hours in the presence or absence of
pretreatment with PEG-catalase and PEG-superoxide dismutase
for 2 hours. Following treatment, cells were stained with
fluorescen-conjugated annexin V/PI and cells were analyzed by
flow cytometry. Bar graph denotes a mean of three independent
experiments.
(TIF)
Figure S2 Effect of Resveratrol on AKT expression and
SHP-TP1 activivity. (A) 5x106 cells were treated with and
without indicated doses of Resveratrol for 24 hours. RNA was
isolated, and reverse transcribed as described in material and
methods. Block RT-PCR for AKT1, AKT2 and AKT3 were
performed for 35 cycles at 55uC. GAPDH was used as an internal
control. (B) SUDHL4 cells were treated with either 25 and 50 mM
Resveratrol or NAC and Resveratrol for 24 hours and cells were
immuno-precipitated with SHP-TP1 antibody. Proteins were
separated on SDS-Page and immuno-blotted with p-Tyrosine
antibody and SHP-TP1 antibody.
(TIF)
Figure S3 Resveratrol down-regulates expression of
IAPs in DLBCL. HBL-1 and SUDHL4 cells were treated with
25 and 50 mM Resveratrol for 24 hours. Following incubation,
cells were harvested and proteins were isolated that were separated
on SDS-Page and immunoblotted with antibodies against XIAP,
cIAP1, Survivin and beta-actin as indicated.
(TIF)
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